Stay updated with breaking news from Epilepsy Study Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in...
A novel investigational antiseizure medication reduces seizure frequency by more than 50% in some patients with treatment-resistant focal epilepsy.
In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.
NEW YORK, Oct. 9, 2023 /PRNewswire/ -- In cases where standard therapies fail, an investigational medication called XEN1101 reduces seizure freque...
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its...